E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with Parkinson's Disease |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Assess the safety of Levodopa-Carbidopa XL Tablets in subjects with Parkinson's disease Assess the bioavailability and pharmacokinetics of 2 regimens of Levodopa-Carbidopa XL Tablets in subjects with Parkinson’s disease. |
|
E.2.2 | Secondary objectives of the trial |
Provide preliminary assessments of the treatment of Parkinson’s disease using a Parkinson’s Disease Diary, tapping speed and tremor score (monitored every 2 hours up to 6 hours after test doses) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients who have provided written informed consent which is written in a manner approved by the Institutional Review Board/Ethics Committee - At least 65% of the subjects should be male - Ambulatory patients who are 58 to 75 years of age. The study population will consist of patients with a diagnosis of idiopathic Parkinson disease and will meet both of the following criteria: 1. PD, defined with at least two of the following cardinal features: rest tremor, bradykinesia, rigidity with PD diagnosis less than or equal to 5 years. 2. Levodopa-responsive idiopathic Parkinson’s disease (PD) patients receiving carbidopa/levodopa (immediate release or sustained-release forms (or both), optimally managed with levodopa intake of no more than 600 mg/day. -Evaluable patients will need to have levodopa-induced peak-effect dyskinesias. - Female patients must not be of childbearing potential (e.g., surgically sterile or be at least one year post-menopausal). - Patients must be willing and able to abide by the dietary requirements of the study - Patients must be willing and able to abide by the restrictions on concomitant medication use that are outlined (restrictions to be determined-see section 9.6). - Patients must be willing to cooperate with study procedures and to be confined within the clinical site’ designated facility overnight, including three consecutive nights.
|
|
E.4 | Principal exclusion criteria |
- Clinical evidence of other parkinsonian syndromes, other than Parkinson’s disease (Progressive supranuclear palsy, Multiple system atrophy, drug-induced parkinsonism, lewy body dementia). -Patients with the “dyskinesia-improvement-dyskinesia” pattern of levodopa responses, or severe wearing-off dystonia will be excluded. - Patients characterized as Hoehn & Yahr Stages >4, without clinical features of dementia, “freezing” of gait, or other significant neurological abnormalities. - Positive test for HIV and Hepatitis A, B, and C - Positive urine drug screen or positive alcohol breathalyzer test. - Insufficiently controlled hypertension (blood pressure > 160/100) - Atrial fibrillation, atrial- nodal- or ventricular arrhythmia, ventricular tachyarrhythmia - History of gastrointestinal surgery or gastrointestinal disease which could affect drug absorption or elimination. - Presence of clinically significant urinary tract obstruction - Patients who donated more than 450 mL of blood within 30 days of the administration of study medication - Patients who have co-morbid neurological or psychiatric disorders (even if they don’t require medications). - Subjects who are taking medications outlined in Section 9.6. - Disruptive non-compliance with requirements of the study causing an inability to collect valid and reliable data. - History of alcohol abuse or drug abuse. - Smokers of more than 10 cigarettes per day (average of 10 weeks prior to the Screening Visit). - Patients who have ingested or who have been administered an investigational compound within 30 days prior to first study medication in this study. - Any condition the clinical investigator deems to be a significant risk to the patient or the scientific integrity of the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety of Levodopa-Carbidopa XL Tablets in subjects with Parkinson's disease. Assess the bioavailability and pharmacokinetics of Levodopa-Carbidopa XL Tablets after a single dose in subjects with Parkinson’s disease.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last contact with the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |